Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:28 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 1,898 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Effect of Drug Clear all

Conditions: Osteoarthritis
Interventions: Lateral wedge orthotic shoe inserts, Standard orthotic shoe inserts; Device
Lead sponsor: Rush University Medical Center; Other
Eligibility: 25 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Drug/Agent Toxicity by Tissue/Organ, Lymphoma
Interventions: denileukin diftitox, dexamethasone; Biological · Drug
Lead sponsor: Ligand Pharmaceuticals; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 11
States / cities: Miami, Florida • Chicago, Illinois • New Orleans, Louisiana + 8 more

Conditions: Prader-Willi Syndrome, Aggression, Self-Injurious Behavior, Pathologic Processes, Behavioral Symptoms, Intellectual Disability, Neurobehavioral Manifestations, Neurologic Manifestations, Nervous System Diseases, Abnormalities, Multiple, Congenital Abnormalities, Chromosome Disorders, Genetic Diseases, Inborn, Obesity, Overnutrition, Nutrition Disorders, Antihypertensive Agents, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action, Physiological Effects of Drugs, Skin-Picking
Interventions: Guanfacine Extended Release, Placebo; Drug · Other
Lead sponsor: Maimonides Medical Center; Other
Eligibility: 6 Years to 35 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Tardive Dyskinesia (TD)
Interventions: Valbenazine, Placebo oral capsule; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 42
States / cities: Little Rock, Arkansas • Anaheim, California • Costa Mesa, California + 35 more

Conditions: Healthy Volunteer
Interventions: fluconazole, itraconazole, rabeprazole, vismodegib; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 2
States / cities: Daytona Beach, Florida • Dallas, Texas

Conditions: Congenital Heart Disease, Disorder of Fetus or Newborn
Interventions: Methylprednisolone, Placebo; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: Up to 30 Days
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 2
States / cities: Atlanta, Georgia • Charleston, South Carolina

Conditions: Healthy
Interventions: Palbociclib alone, Palbociclib + Rabeprazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: South Miami, Florida

Conditions: Liver Transplantation, Immune Tolerance, Immune Tolerance/Drug Effects, Graft Survival, Hematopoietic Stem Cell, Chimerism, Immunosuppression After Liver Transplantation, Immunosuppression Disorders, End Stage Liver Disease
Interventions: Donor Hematopoietic Stem and Progenitor Cell Infusion; Biological
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Colorectal Cancer
Interventions: KRN330, Irinotecan; Biological · Drug
Lead sponsor: Kyowa Kirin Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 12
States / cities: Huntsville, Alabama • Tucson, Arizona • Los Angeles, California + 8 more

Conditions: Proctitis, Proctosigmoiditis
Interventions: Budesonide, Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 265 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 63
States / cities: Birmingham, Alabama • Huntsville, Alabama • Jonesboro, Arkansas + 60 more

Conditions: Healthy Participants
Interventions: Mavacamten Capsule 1, Mavacamten Capsule 2, Mavacamten Capsule 3; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 3
States / cities: Anaheim, California • Miami, Florida • Springfield, Missouri

Conditions: Opioid Use
Interventions: Personal Feedback, Peer Normative Comparison Feedback; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 99 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Pharmacokinetics
Interventions: colchicine, clarithromycin; Drug
Lead sponsor: Mutual Pharmaceutical Company, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Opioid-Related Disorders
Interventions: oxycodone and naltrexone; Drug
Lead sponsor: Pain Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Participants
Interventions: rosuvastatin, BMS-963272; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Healthy Volunteer
Interventions: varegacestat, Itraconazole (200 mg); Drug
Lead sponsor: Immunome, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Nemiralisib, Itraconazole; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Opioid Overdose, Drug Overdose
Interventions: RAPIDS Intervention, Standard OEND; Behavioral
Lead sponsor: Brown University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 509 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Nicotine Withdrawal, Nicotine Addiction, Drug Effect
Interventions: Nicotine, Cigarette; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years and older
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Skin Diseases
Interventions: 3% Benzoyl Peroxide, 3% Benzoyl Peroxide Placebo, Neutrogena Rapid Clear®; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years to 45 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: High Point, North Carolina

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 3,669 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2006
U.S. locations: 91
States / cities: Mill Valley, California • Oakland, California • San Francisco, California + 31 more

Conditions: Schizophrenia, Bipolar Disorder, Psychotic Disorders
Interventions: divalproex sodium ER/paliperidone ER; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 3
States / cities: Kissimmee, Florida • Austin, Texas • Portsmount, Virginia

Conditions: Healthy
Interventions: MK-7262, Enlicitide; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Peripheral Nerve Block, Anxiety, Preoperative Anxiety
Interventions: Music, Midazolam; Other · Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

A Study of Orthotic Shoe Inserts for Controlling Osteoarthritic Knee Pain

Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma

Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome

Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia

A Drug-Drug Interaction Study of the Effect of Rabeprazole, Itraconazole or Fluconazole on the Pharmacokinetics of Vismodegib

Corticosteroid Therapy in Neonates Undergoing Cardiopulmonary Bypass

Drug Interaction Study To Investigate The Potential Effect Of Proton Pump Inhibitor On The Pharmacokinetics Of Palbociclib (PD-0332991)

Immune Tolerance Induction After Liver Transplantation

Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer

Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis

A Study to Assess the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants

Peer Comparison Feedback on Opioid Prescribing

Drug-Drug Interaction Study of Colchicine and Clarithromycin

Study to Evaluate the Subjective Effects of PTI-801 in Non-Physically Dependent Subjects With a History of Drug Abuse

A Study to Assess the Drug-drug Interaction of BMS-963272 and Rosuvastatin

A Phase 1 Study to Examine the Effects of Itraconazole After Single Dose Administration of Varegacestat (AL102) to Healthy Participants

A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics (PK) of Nemiralisib

The Rhode Island Prescription and Illicit Drug Study

Acute Pharmacokinetic and Pharmacodynamic Effects of "Tobacco-Free" Oral Nicotine Pouches in Smokers

A Five Day Clinical Study to Examine the Effects of a Benzoyl Peroxide Treatment on Facial Acne Lesions

A Study of the Long-Term Outcomes of HIV-Positive Patients

A Drug Interaction Study of Valproic Acid and Paliperidone Extended-Release (ER) in Patients With Schizophrenia, Bipolar I Disorder, or Schizoaffective Disorder

A Clinical Study of MK-7262 and Enlicitide in Healthy Participants (MK-7262-003)

Music vs Midazolam During Preop Nerve Block Placement - Part 2 Study On Anxiolytic Options Before Peripheral Nerve Blocks